Close Menu

This story has been updated with additional details on the FDA approved companion test for Alunbrig and about how patients were genetically tested in the ALTA 1L study. 

NEW YORK – The US Food and Drug Administration on Friday approved Takeda Pharmaceutical's brigatinib (Alunbrig) as a treatment for ALK-positive, metastatic non-small cell lung cancer.

The agency simultaneoulsy approved Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit to identify patients with ALK rearrangements who are likely to benefit from brigatinib.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.